Novavax vaccine shows 96 per cent efficacy against original coronavirus, 86 per cent against UK variant Read more
Low patient accrual rates cause termination of over 25 per cent rare disease trials: GlobalData Read more
Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial Read more